Neurotech founder Adrian Trevisan (left) with chief executive Wolfgang Storf.

Neurotech raises $4m for medical device

Medical technology company Neurotech International has tapped investors for $4 million to fund further development of its Mente Autism device.

Perth-based Neurotech, which listed on the ASX last year through a $7 million IPO, raised the funds through the placement of 20 million shares at 20 cents each, representing a 10.5 per cent discount to its five-day volume-weighted average price.

The proceeds will be used to further develop and enhance its Mente Autism product, which uses neurofeedback technology to help children with autism spectrum disorder.


(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

Sign up here for free access to 7 articles per month + twice daily business email alerts.

Thanks! This question prevents spammers...
Enter the characters shown in the image.

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 31/10/17

1 year TSR5 year TSR
thNeurotech International0%0%
66thZelda Therapeutics193%24%
196thMGC Pharmaceuticals42%-13%
809thDotz Nano-86%-70%
726 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


179th↓MGC Pharmaceuticals$120k
181st-Neurotech International$104k
182nd-Zelda Therapeutics$100k
183rd-Dotz Nano$99k
231 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer